[go: up one dir, main page]

PA8789901A1 - Derivados de la 6-cicloamino-3-(piridazin-4-il)imidazol(1,2-b) priridazina, su preparación y su aplicación en terapéuta - Google Patents

Derivados de la 6-cicloamino-3-(piridazin-4-il)imidazol(1,2-b) priridazina, su preparación y su aplicación en terapéuta

Info

Publication number
PA8789901A1
PA8789901A1 PA20088789901A PA8789901A PA8789901A1 PA 8789901 A1 PA8789901 A1 PA 8789901A1 PA 20088789901 A PA20088789901 A PA 20088789901A PA 8789901 A PA8789901 A PA 8789901A PA 8789901 A1 PA8789901 A1 PA 8789901A1
Authority
PA
Panama
Prior art keywords
group
piridazin
derivatives
preparation
application
Prior art date
Application number
PA20088789901A
Other languages
English (en)
Inventor
Philippe Burnier
Adrien Tak Li
Frederic Puech
Des Combes Sylvain Cote
Yulin Chiang
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PA8789901A1 publication Critical patent/PA8789901A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA INVENCION SE REFIERE A DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-B]PIRIDAZINA, DE FÓRMULA GENERAL (I): EN LA QUE R2 REPRESENTA UN GRUPO ARILO OPCIONALMENTE SUSTITUIDO; A REPRESENTA UN GRUPO ALQUILENO C1-7 OPCIONALMENTE SUSTITUIDO; B REPRESENTA UN GRUPO ALQUILENO C1-7 OPCIONALMENTE SUSTITUIDO; L REPRESENTA BIEN UN ÁTOMO DE NITRÓGENO OPCIONALMENTE SUSTITUIDO CON UN GRUPO RC O RD, O BIEN UN ÁTOMO DE CARBONO SUSTITUIDO CON UN GRUPO RE1 Y UN GRUPO RD O DOS GRUPOS RE2, ESTANDO LOS ÁTOMOS DE CARBONO A Y DE B OPCIONALMENTE SUSTITUIDOS CON UNO O VARIOS GRUPOS RF IDÉNTICOS O DIFERENTES EL UNO DEL OTRO; R7 Y R8 REPRESENTAN, INDEPENDIENTEMENTE EL UNO DEL OTRO, UN ÁTOMO DE HIDRÓGENO O UN GRUPO ALQUILO C1-6. PROCEDIMIENTO DE PREPARACIÓN Y APLICACIÓN EN TERAPÉUTICA.
PA20088789901A 2007-07-19 2008-07-15 Derivados de la 6-cicloamino-3-(piridazin-4-il)imidazol(1,2-b) priridazina, su preparación y su aplicación en terapéuta PA8789901A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95071107P 2007-07-19 2007-07-19
FR0705224A FR2918986B1 (fr) 2007-07-19 2007-07-19 Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
PA8789901A1 true PA8789901A1 (es) 2009-02-09

Family

ID=39183122

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088789901A PA8789901A1 (es) 2007-07-19 2008-07-15 Derivados de la 6-cicloamino-3-(piridazin-4-il)imidazol(1,2-b) priridazina, su preparación y su aplicación en terapéuta

Country Status (22)

Country Link
US (2) US8455491B2 (es)
EP (1) EP2178879B1 (es)
JP (1) JP5431319B2 (es)
KR (1) KR20100041771A (es)
CN (1) CN101784552A (es)
AR (1) AR069272A1 (es)
AU (1) AU2008300449A1 (es)
BR (1) BRPI0814510A2 (es)
CA (1) CA2693116A1 (es)
CL (1) CL2008002138A1 (es)
CO (1) CO6290690A2 (es)
EA (1) EA016376B1 (es)
ES (1) ES2429765T3 (es)
FR (1) FR2918986B1 (es)
MA (1) MA31616B1 (es)
NZ (1) NZ582683A (es)
PA (1) PA8789901A1 (es)
PE (1) PE20090493A1 (es)
TW (1) TW200914456A (es)
UY (1) UY31236A1 (es)
WO (1) WO2009037394A2 (es)
ZA (1) ZA201001214B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
FR2939134A1 (fr) * 2008-12-01 2010-06-04 Sanofi Aventis Derives de 6-cycloamino-3-(1h-pyrrolo°2,3-b!pyridin-4-yl) imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique
FR2940284B1 (fr) * 2008-12-19 2011-02-18 Sanofi Aventis Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
FR2940285A1 (fr) * 2008-12-19 2010-06-25 Sanofi Aventis Derives de 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo °1,2-b!-pyridazine et 6-cycloamino-2-furanyl-3- (pyridin-4-yl)imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique
WO2011041154A1 (en) 2009-10-01 2011-04-07 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
US8680275B2 (en) 2009-10-23 2014-03-25 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
HUE043962T2 (hu) * 2009-10-23 2019-09-30 Janssen Pharmaceutica Nv Diszubsztituált oktahidro-pirrolo[3,4-C]pirrolok mint orexin receptor modulátorok
NZ599597A (en) 2009-10-30 2013-05-31 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
EP2585048B1 (en) 2010-06-23 2018-04-11 CymaBay Therapeutics, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
CN103097380B (zh) * 2010-08-09 2015-06-03 株式会社创药分子设计 酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂
JP5937102B2 (ja) 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ1デルタ(ck1デルタ)阻害剤
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
WO2013000924A1 (en) 2011-06-27 2013-01-03 Janssen Pharmaceutica Nv 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
WO2014001314A1 (en) 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
AU2013289284B2 (en) 2012-07-09 2017-03-30 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
JP6283688B2 (ja) * 2012-12-21 2018-02-21 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company カゼインキナーゼ1d/e阻害剤としての新規なピラゾール置換のイミダゾピラジン
WO2014100533A1 (en) 2012-12-21 2014-06-26 Bristol-Myers Squibb Company NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS
GB201321734D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
CN106029075A (zh) * 2014-01-09 2016-10-12 细胞内治疗公司 有机化合物
CN108883110B (zh) 2016-03-10 2022-05-27 詹森药业有限公司 使用食欲素-2受体拮抗剂治疗抑郁症的方法
CA3032432A1 (en) 2016-08-03 2018-02-08 Charles A. Mcwherter Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
US11014927B2 (en) 2017-03-20 2021-05-25 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
SG11202007422QA (en) 2018-02-05 2020-09-29 Alkermes Inc Compounds for the treatment of pain
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
EP4031132A4 (en) 2019-09-19 2023-09-13 Forma Therapeutics, Inc. Activating pyruvate kinase r
WO2021190615A1 (en) * 2020-03-27 2021-09-30 Gritscience Biopharmaceuticals Co., Ltd. Compounds as casein kinase inhibitors
WO2021190616A1 (en) * 2020-03-27 2021-09-30 Gritscience Biopharmaceuticals Co., Ltd. Methods for inhibiting casein kinases
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
MX2024004444A (es) 2021-10-14 2024-05-08 Incyte Corp Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras).

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001333A1 (en) * 1987-08-07 1989-02-23 The Australian National University IMIDAZO[1,2-b]PYRIDAZINES
US6555328B1 (en) 1999-06-08 2003-04-29 Aventis Pharmaceuticals Inc. Screening methods for altering circadian rhythms and for human casein kinase I δ and/or ε phosphorylation of human clock proteins, period 1, -2 and -3
RS50823B (sr) * 2003-12-11 2010-08-31 Aventis Pharmaceuticals Inc. Supstituisani 1h-pirolo[3,2-b, 3,2-c, i 2,3-c]piridin-2-karboksamidi i srodni analozi kao inhibitori kazein kinaze i epsilon
CA2555263A1 (en) * 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
US20100216798A1 (en) * 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
JP2010533686A (ja) 2010-10-28
FR2918986B1 (fr) 2009-09-04
CL2008002138A1 (es) 2009-10-23
ES2429765T3 (es) 2013-11-15
CO6290690A2 (es) 2011-06-20
MA31616B1 (fr) 2010-08-02
NZ582683A (en) 2011-07-29
JP5431319B2 (ja) 2014-03-05
BRPI0814510A2 (pt) 2015-02-03
US20100152157A1 (en) 2010-06-17
EA016376B1 (ru) 2012-04-30
KR20100041771A (ko) 2010-04-22
US9108971B2 (en) 2015-08-18
EP2178879B1 (fr) 2013-07-03
AR069272A1 (es) 2010-01-13
PE20090493A1 (es) 2009-05-27
US8455491B2 (en) 2013-06-04
EP2178879A2 (fr) 2010-04-28
TW200914456A (en) 2009-04-01
US20130245023A1 (en) 2013-09-19
AU2008300449A1 (en) 2009-03-26
EA201070161A1 (ru) 2010-08-30
CA2693116A1 (fr) 2009-03-26
WO2009037394A2 (fr) 2009-03-26
ZA201001214B (en) 2011-05-25
UY31236A1 (es) 2009-03-02
FR2918986A1 (fr) 2009-01-23
CN101784552A (zh) 2010-07-21
WO2009037394A3 (fr) 2009-06-18

Similar Documents

Publication Publication Date Title
PA8789901A1 (es) Derivados de la 6-cicloamino-3-(piridazin-4-il)imidazol(1,2-b) priridazina, su preparación y su aplicación en terapéuta
PA8786101A1 (es) "DERIVADOS DE 6-CICLOAMINO-3-(PIRIDIN-4-IL) IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA"
CR11546A (es) Derivados de carboxamidas azabiciclicas, su preparacion y su aplicacion en terapeutica
ECSP13012771A (es) Compuestos heterocíclicos nitrogenados sustituidos fusionados en posición 6,6 y usos de los mismos
PA8813101A1 (es) Derivados bicílicos de carboxamidas aza-bicíclicas,su preparación y su aplicación terapéutica
AR075243A1 (es) Derivados del 1-fenil-2-piridinil alquil alcohol como inhibidores de fosfodiesterasa
DOP2010000215A (es) Derivados de carboxamidas azabiciclicas, su preparacion y su aplicacion en terapeutica
CO6341631A2 (es) Derivados de 1,2,4 - oxadiazol y su uso terapéutico
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
ECSP088113A (es) Nuevos derivados de pirazina
ECSP099216A (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY29246A1 (es) Nuevos compuestos
HN2009000502A (es) DERIVADOS DE 2- ARIL-6-FENIL-IMIDAZO[ 1,2-a] PIRIDINAS SU PREPARACION Y SU APLICACION EN TERAPEUTICA
AR067316A1 (es) Moleculas secuestradoras de oxigeno, articulos que las contienen y metodos para su uso
PA8797301A1 (es) Derivados de nicotinamida, su preparacion y su aplicacion en terapeutica
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
CR11251A (es) Depsipeptidos ciclicos y usos de los mismos
IN2015DN01315A (es)
EA201200602A1 (ru) Индазолы и пиразолопиридины в качестве антагонистов рецептора ccr1
CO6150181A2 (es) Compuesto 6-(bencilo sustituido con heterociclo)-4-oxoquinolina y su uso como inhibidor de integrasa vih
AR076665A1 (es) Derivados de 2-cicloamino-5-(piridin-4-il)imidazo(2,1-b)(1,3,4)tiadiazol su preparacion y su aplicacion en terapeutica
NI201000134A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
CO6321287A2 (es) Derivados de aminopiridinamida como inhibidores de calicreina tisular
PA8849801A1 (es) Derivados de 6-cicloamino-3-(1h-pirrolo[2,3-b]piridin-4-il)imidazo[1,2-b]-piridazina, su preparación en terapéutica
BR112013001368A2 (pt) 4-(4-halogenalquil-3-tiobenzoil)pirazól e uso como herbicidas dos mesmos